

Congenital heart disease, pulmonary arterial hypertension and the UK's Drivers and Vehicle Licensing Agency: controversial new guidance

Andrew Constantine^{1,2}, Robert Tulloh³, Robin Condliffe⁴, Paul Clift⁵ and Konstantinos Dimopoulos^{1,2}; on behalf of the CHAMPION Steering Committee

¹Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK; ²National Heart and Lung Institute, Imperial College London, London, UK; ³Bristol Heart Institute, University Hospitals Bristol NHS Foundation Trust, Bristol, UK; ⁴Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK; ⁵Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, UK

Keywords

adult congenital heart disease, pulmonary hypertension, driving restrictions, UK guidelines

Date received: 17 September 2019; accepted: 20 September 2019

Pulmonary Circulation 2019; 9(4) 1–2

DOI: 10.1177/2045894019882627

Recently, the UK's Driver & Vehicle Licensing Agency (DVLA) published updated guidance for medical professionals on assessing fitness to drive.¹ This included updates for adults with congenital heart disease (ACHD) and a new section for those with pulmonary hypertension. There is some overlap in these conditions, with pulmonary arterial hypertension (PAH) affecting 5–10% of congenital heart disease patients. Both PAH and ACHD are the remit of the specialist, and in both conditions social independence and psychological wellbeing are key goals of care. Driving can enhance an individual's independence by facilitating engagement in social roles, including employment, family life and peer relationships. In the presence of medical conditions that can significantly affect exercise tolerance, this freedom must be balanced against the risk of a sudden disabling event.

In the new guidance, anyone with ACHD and symptoms, including any severity of palpitations or breathlessness, must stop driving immediately and must notify the DVLA. Patients with PAH who are under the care of a specialist centre may only drive after specialist assessment, and only if the assessment concludes that there is an annual risk of a disabling event of <20%. The requirements are even stricter for group 2 licence holders. Failure to disclose

a medical condition that affects driving eligibility can lead to a fine of up to £1000, and criminal prosecution if driving results in a road traffic collision.

These changes are significant. Previously, patients with either condition could continue to hold a group 1 licence provided there was “no other disqualifying condition”. Under the new guidance, however, patients with symptomatic congenital heart disease may face a blanket ban on driving.

Inconsistencies in the guidelines disadvantage our patients. For example, palpitations are included in the list of prohibitive symptoms in ACHD. For non-ACHD patients with arrhythmia, driving must stop only if the arrhythmia has caused or is likely to cause incapacity. This creates a double standard – one rule for ACHD patients and one rule for everyone else.

For PAH, specialist assessment is required to ensure that the annual risk of a disabling event is <20%. However, current validated risk stratification models only assess overall mortality risk; none focus on sudden death or syncope.^{2–6}

Corresponding author:

Konstantinos Dimopoulos, Adult Congenital Heart Centre, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London SW3 6NP, UK.
Email: k.dimopoulos02@gmail.com



Creative Commons CC-BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<http://www.creativecommons.org/licenses/by/4.0/>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

© The Author(s) 2019.
Article reuse guidelines:
sagepub.com/journals-permissions
journals.sagepub.com/home/pul



Trial outcomes in PAH do not report ‘annual disabling event rate’, which makes the provision of meaningful, evidence-based estimates a fool’s errand.

In addition to being evidence-based and fair, obligations placed upon the health service need to be feasible and cost-effective. Full implementation of this DVLA guidance, however, places an unrealistic burden on healthcare practitioners. Additional ‘specialist assessment’ of 5500 adults with PAH receiving follow-up in dedicated centres⁷ represents a large increase in workload. For ACHD specialists, who are faced with an estimated UK population of 120,000 patients,^{8,9} the task is even more colossal. Such ‘inclusive’ guidance requires clinicians to make an updated assessment of driving eligibility in every consultation, with little evidence on how to achieve this in an extremely heterogeneous population. In ACHD, the same symptom can have widely different implications depending on underlying anatomy. For example, palpitations due to atrial fibrillation in the context of a Fontan circulation signals a significantly increased one-year risk of death (non-sudden), whereas this is not the case for a patient with an atrial septal defect. Guidance has to be lesion-specific to reflect true risk. By the same token, symptoms that are not causing incapacity at the wheel should not affect one’s eligibility to drive unless there is a disease-specific cause for concern.

Ultimately, the limitation of the “law, marching with medicine but in the rear and limping a little” (Lord Justice Windeyer, 1970)¹⁰ should not be replaced by law racing ahead of scientific knowledge, leaving a trail of anxious patients and confused clinicians in its wake. The current guidance for ACHD and PAH is controversial and signals the immediate need for collaboration and consensus across experts nationwide. The goal should be to urgently put in place practical and easy-to-implement guidance, which reflects current medical knowledge and protects the public and the patient. Future studies are needed to inform DVLA guidance. In the meantime, we strongly recommend that current guidance is urgently revised seeking expert consensus opinion.

Conflict of interest

Dr. Constantine reports grants from Actelion UK, outside the submitted work; Dr. Tulloh reports personal fees and non-financial support from Actelion Pharmaceuticals, personal fees from Pfizer, personal fees from Abbott International, personal fees from GlaxoSmithKline, personal fees from Bayer, outside the submitted work; Dr. Condliffe reports personal fees and non-financial support from Actelion UK, personal fees from Bayer, personal fees from GlaxoSmithKline, outside the submitted work; Dr. Clift reports grants, personal fees and non-financial support from

Actelion Pharmaceuticals, personal fees from Bayer, outside the submitted work; Dr. Dimopoulos reports personal fees from Pfizer, grants, personal fees and non-financial support from Actelion, outside the submitted work.

Funding

Actelion Pharmaceuticals UK Ltd provided funding support for the publication.

References

1. GOV.UK. Assessing fitness to drive: a guide for medical professionals, www.gov.uk/government/publications/assessing-fitness-to-drive-a-guide-for-medical-professionals (2019, accessed 1 October 2019).
2. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. *Eur Respir J* 2017; 50: 1700740.
3. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. *Eur Respir J* 2017; 50: 1700889.
4. Hoeper MM, Pittrow D, Opitz C, et al. Risk assessment in pulmonary arterial hypertension. *Eur Respir J* 2018; 51: 1702606.
5. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation* 2010; 122: 164–172.
6. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Respir J* 2015; 46: 903–975.
7. NHS Digital. National Audit of Pulmonary Hypertension, 9th Annual Report, <https://digital.nhs.uk/data-and-information/publications/statistical/national-pulmonary-hypertension-audit/2018/2018> (2018, accessed 27 April 2019).
8. Population estimates – Office for National Statistics, www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates#publications (2018, accessed 26 April 2019).
9. van der Bom T, Bouma BJ, Meijboom FJ, Zwinderman AH and Mulder BJM. The prevalence of adult congenital heart disease, results from a systematic review and evidence-based calculation. *Am Heart J* 2012; 164: 568–575.
10. Mount Isa Mines Ltd v. Pusey, 1970. High Court of Australia 125 CLR 383. *Jade* (Online). Available at: <https://jade.io/article/66238> (accessed 1 October 2019).